Biotech leader Greg Verdine celebrates major IPO and $263 million funding round
Scientist-turned-entrepreneur Greg Verdine saw his company Parabilis Medicines go public in a large IPO, while his other firm LifeMine secured $263 million to advance a transplant-focused drug.
Greg Verdine, who moved from research to biotech leadership, marked a successful year as Parabilis Medicines listed on the stock market in one of the sector’s biggest recent offerings. At the same time, his venture LifeMine announced a $263 million financing round aimed at developing a therapy that could improve organ-transplant outcomes and treat autoimmune diseases. Verdine highlighted how the science he pursued fifteen years ago is now influencing pancreatic cancer treatment and broader medical applications.
Why it matters
The IPO and funding boost could speed delivery of new treatments for transplants and autoimmune diseases.
In this story